MR Quantitative Susceptibility Imaging for the Evaluation of Iron Loading in the Brains of Patients with β-Thalassemia Major

References

1. 1.↵
   1. Olivieri NF,
   2. Brittenham GM

   . Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739–61

   FREE Full Text
2. 2.↵
   1. Economou M,
   2. Zafeiriou DI,
   3. Kontopoulos E,
   4. et al

   . Neurophysiologic and intellectual evaluation of beta-thalassemia patients. Brain Dev 2006;28:14–18

   CrossRefPubMed
3. 3.↵
   1. Monastero R,
   2. Monastero G,
   3. Ciaccio C,
   4. et al

   . Cognitive deficits in beta-thalassemia major. Acta Neurol Scand 2000;102:162–68

   CrossRefPubMed
4. 4.↵
   1. Brass SD,
   2. Chen NK,
   3. Mulkern RV,
   4. et al

   . Magnetic resonance imaging of iron deposition in neurological disorders. Topics Magn Reson Imaging 2006;17:31–40

   CrossRef
5. 5.↵
   1. Haacke EM,
   2. Mittal S,
   3. Wu Z,
   4. et al

   . Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. Am J Neuroradiol 2009;30:19–30

   Abstract/FREE Full Text
6. 6.↵
   1. Mittal S,
   2. Wu Z,
   3. Neelavalli J,
   4. et al

   . Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 2009;30:232–52

   Abstract/FREE Full Text
7. 7.↵
   1. de Rochefort L,
   2. Brown R,
   3. Prince MR,
   4. et al

   . Quantitative MR susceptibility mapping using piece-wise constant regularized inversion of the magnetic field. Magn Reson Med 2008;60:1003–09

   CrossRefPubMed
8. 8.↵
   1. Kressler B,
   2. de Rochefort L,
   3. Liu T,
   4. et al

   . Nonlinear regularization for per voxel estimation of magnetic susceptibility distributions from MRI field maps. IEEE Trans Med Imaging 2010;29:273–81

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Li W,
   2. Wu B,
   3. Liu C

   . Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. NeuroImage 2011;55:1645–56

   CrossRefPubMed
10. 10.↵
    1. Liu T,
    2. Liu J,
    3. de Rochefort L,
    4. et al

    . Morphology enabled dipole inversion (MEDI) from a single-angle acquisition: comparison with COSMOS in human brain imaging. Magn Reson Med 2011;66:777–83

    CrossRefPubMed
11. 11.↵
    1. Shmueli K,
    2. de Zwart JA,
    3. van Gelderen P,
    4. et al

    . Magnetic susceptibility mapping of brain tissue in vivo using MRI phase data. Magn Reson Med 2009;62:1510–22

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Wharton S,
    2. Bowtell R

    . Whole-brain susceptibility mapping at high field: a comparison of multiple- and single-orientation methods. NeuroImage 2010;53:515–25

    CrossRefPubMed
13. 13.↵
    1. Lotfipour AK,
    2. Wharton S,
    3. Schwarz ST,
    4. et al

    . High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Res Imaging 2012;35:48–55

    CrossRefPubMed
14. 14.↵
    1. Zheng W,
    2. Nichol H,
    3. Liu S,
    4. et al

    . Measuring iron in the brain using quantitative susceptibility mapping and X-ray fluorescence imaging. NeuroImage 2013;78:68–74

    CrossRefPubMed
15. 15.↵
    1. Schweser F,
    2. Deistung A,
    3. Lehr BW,
    4. et al

    . Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: an approach to in vivo brain iron metabolism? NeuroImage 2011;54:2789–807

    CrossRefPubMed
16. 16.↵
    1. Qiu D,
    2. Zaharchuk G,
    3. Feng S,
    4. et al

    . Quantitative Susceptibility Imaging using L1 regularized reConstruction with sparsity promoting transformation: SILC. Proceedings of International Society of Magnetic Resonance in Medicine Annual Meeting 2011;19:4470
17. 17.↵
    1. Chui CK

    . An Introduction to Wavelets. San Diego: Academic Press; 1992
18. 18.↵
    1. Wu B,
    2. Li W,
    3. Guidon A,
    4. et al

    . Whole brain susceptibility mapping using compressed sensing. Magn Reson Med 2012;67:137–47

    CrossRefPubMed
19. 19.↵
    1. Pfefferbaum A,
    2. Adalsteinsson E,
    3. Rohlfing T,
    4. et al

    . MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods. NeuroImage 2009;47:493–500

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Hallgren B,
    2. Sourander P

    . The effect of age on the non-haemin iron in the human brain. J Neurochem 1958;3:41–51

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Rund D,
    2. Rachmilewitz E

    . Beta-thalassemia. N Engl J Med 2005;353:1135–46

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Rouault TA,
    2. Zhang DL,
    3. Jeong SY

    . Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. Metab Brain Dis 2009;24:673–84

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Li W,
    2. Wu B,
    3. Batrachenko A,
    4. et al

    . Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan. Hum Brain Mapp 2014;35:2698–713

    CrossRefPubMed
24. 24.↵
    1. Moshtaghi-Kashanian GR,
    2. Razavi F

    . Ghrelin and leptin levels in relation to puberty and reproductive function in patients with beta-thalassemia. Hormones 2009;8:207–13

    CrossRefPubMed
25. 25.↵
    1. Metafratzi Z,
    2. Argyropoulou MI,
    3. Kiortsis DN,
    4. et al

    . T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. Br J Radiol 2001;74:407–10

    Abstract/FREE Full Text
26. 26.↵
    1. Youdim MB

    . Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotox Res 2008;14:45–56

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Pandolfo M,
    2. Hausmann L

    . Deferiprone for the treatment of Friedreich's ataxia. J Neurochem 2013;126(Suppl 1):142–46

    CrossRefPubMed
28. 28.↵
    1. Lim IA,
    2. Faria AV,
    3. Li X,
    4. et al

    . Human brain atlas for automated region of interest selection in quantitative susceptibility mapping: application to determine iron content in deep gray matter structures. NeuroImage 2013;82:449–69

    CrossRefPubMed